Nearly All Nursing Homes Fail Federal Rules on Anti-Psychotics
A year ago, the OIG, which is a branch of the U.S. Department of Health and Human Services, published a report saying that about half of anti-psychotic medications given to Medicare beneficiaries in nursing homes were not for medically accepted indications, and one in five were not given in accordance with federal safeguards to protect residents from unnecessary use.
The latest report takes the investigation one step further by looking at whether all four requirements in the process of determining appropriate use of those anti-psychotics in nursing homes were met.
The OIG recommends that the Centers for Medicare & Medicaid Services should do more to improve the process, specifically by modifying the survey "to target a small subsample of residents receiving anti-psychotic drugs focusing on the quality of care for these particularly vulnerable residents."
Also, CMS could require that nursing facilities document any efforts “to include the participation of residents, their families, or their legal representatives" in developing care plans.
- Readmissions: No Quick Fix to Costly Hospital Challenge
- How Top-Ranked MA Plans Earn Their Stars
- How Telehealth Pays Off for Providers, Patients
- House Calls Key to Pioneer ACO Success
- 4 Ways to Lower the Cost to Collect from Self-Pay Patients
- Defensive Medicine Still Prevalent Despite Tort Reform
- Ebola: Health Officials Try to Quell Front Line Fears
- How Hospitals Can Become 'Upstreamists'
- 'Overtreatment' Debate Circles Back to Lung Cancer Screening
- 4 Tips for Managing Employed Physicians